Ignite Creation Date:
2024-05-06 @ 5:40 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05380024
Status:
UNKNOWN
Last Update Posted:
2022-08-18
First Post:
2022-05-13
Brief Title:
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-17
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-13
First Submit QC Date:
May 13 2022
Study First Post Date:
2022-05-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-17
Last Update Post Date:
2022-08-18
Last Update Post Date Type:
ACTUAL